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itroglycerin Hits the Nerve
ole for Mitochondrial
ldehyde Dehydrogenase?*
lrich Hink, MD,
ohamed-Saiel S. Alhamdani, MD,
homas Münzel, MD, FAHA
ainz, Germany
rganic nitrates are still widely used for the treatment of
cute and chronic angina and congestive heart failure.
hen given acutely, their effectiveness is indisputable; in
ontrast, their long-term efficacy is limited because of
erious side effects such as the development of tolerance and
ndothelial dysfunction. Results of a large observational
tudy even indicate that nitrates had negative effects on the
rognosis in patients who had experienced a myocardial
nfarction (1). Within the last 5 to 6 years, increasing
vidence has supported a crucial role of the mitochondrial
ldehyde dehydrogenase (ALDH-2) in the bioactivation
rocess of nitroglycerin (GTN) (2). Nevertheless, the pre-
ise contribution of GTN-stimulated releases of other
asoactive substances such as prostacyclin and the neu-
opeptide calcitonin gene-related peptide (CGRP) remains
bscure.
See page 953
LDH-2 and GTN Bioactivation
itroglycerin exerts its beneficial, anti-ischemic effects
ia vasodilation of large coronary arteries, collateral
essels, and venous capacitance vessels while minimally
ffecting arteriolar tone (3). Nitroglycerin activates the
oluble guanylyl cyclase (sGC), leading to cyclic guanosine
=,5=-monophosphate (cGMP) formation, which activates
GMP-dependent protein kinase (cGK-I). The cGK-I in
urn causes vasorelaxation via phosphorylation of several
roteins that regulate intracellular Ca2 mobilization (4).
In 2002, Chen et al. (2) proposed that ALDH-2 is the
redominant bioactivating enzyme for GTN. The investi-
ators convincingly showed that ALDH-2, a mitochondrial
nzyme, can act as a GTN-reductase to form 1,2-glyceryl
initrate and a nitrite intermediate (NOx), leading to cGMP
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or them
merican College of Cardiology.
From the Medizinische Klinik, Johannes Gutenberg Universität, Mainz, Germany.ormation, and subsequently to vasodilation (2) (Fig. 1). The
ritical role of the ALDH-2 in GTN-induced vasodilation
as further substantiated by studies in humans with a
lu504Lys ALDH-2-polymorphism. This polymorphism
s characterized by a functional loss of ALDH-2 activity and
markedly reduced GTN bioactivation and vasodilatory
apacity of GTN (5).
alcitonin Gene-Related Peptide (CGRP)
ontributes to GTN-Induced Vasodilation
nd Inhibition of Platelet Aggregation
ei et al. (6) were the first to report in 1992 that
itrovasodilators such as GTN and sodium nitroprusside
timulate sensory nerves to release CGRP, which in turn
elaxes cerebral vascular smooth muscle in cats by activating
uanylate cyclase. The investigators suggested a role of
GRP in GTN-induced vasodilation and headache (6).
he role of CGRP as a mediator of GTN effects was further
ubstantiated by the observation that pre-incubation of rat
orta with GTN increases the release of CGRP (7), an effect
hat was blunted by the specific competitive CGRP receptor
ntagonist CGRP8-37 and by capsaicin, which desensitizes
ensory nerves by transmitter depletion (8). Experimental
tudies showed that GTN-induced blood pressure decreases
n rats were paralleled by increases in plasma concentrations
f CGRP (9). In addition, GTN-induced inhibition of
hole blood aggregation was partly inhibited by CGRP8-37
10), suggesting that CGRP is also, at least partially,
nvolved in the antiaggregatory effects of GTN.
here Is CGRP Coming From?
he 37-amino-acid vasoactive neuropeptide CGRP and
ther neuropeptides, like tachykinins, are coexpressed in
rimary afferent neurons that belong to the nonadrenergic
oncholinergic (NANC) nervous system, which is involved
n the sensation of pain (11). Furthermore, NANC neurons
orming CGRP are distributed among autonomic fibers
hat innervate the media of the vasculature (12). The
ocation of these nerve endings as well as the potent
asodilatory effects of CGRP (13) support the concept that
CGRP serves as a modulator of peripheral vascular tone.
mportantly, there is evidence that CGRP colocalizes with
itric oxide (NO)-synthase in perivascular NANC nerves of
arious vascular beds (14).
olecular Mechanisms Underlying CGRP Release
he mechanism leading to CGRP release, however, is still
nder debate. As mentioned above, in the cerebral feline
irculation the vasodilator response to GTN and sodium
itroprusside, but not that to adenosine, is attenuated by the
nhibitor CGRP8-37 (6), suggesting that CGRP release is
aused by both nitrovasodilators. In the rat aorta, relaxations
o GTN, but not sodium nitroprusside, are affected by
GRP8-37 (7,15). Whether NO directly or its second
essenger cGMP indirectly stimulates the release of CGRP
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Editorial Comment September 9, 2008:961–3emains contradictory. An inhibitor of guanylate cyclase,
ethylene blue, attenuated CGRP release in rat femoral
essels by GTN (9), but not capsaicin-evoked CGRP
elease in the spinal cord (16). The latter showed pro-
ounced modulation by NO but not by cGMP levels
16,17). Furthermore, the platelet inhibitory effects of
GRP in response to GTN were inhibited by NG-
onomethyl-L-arginine, a NO synthase inhibitor, and by
he deletion of the endothelial NO synthase gene, suggest-
ng that GTN antiplatelet activity of CGRP is mediated
rimarily through the activation of eNOS (10).
In this issue of the Journal, Guo et al. (18) report for the
rst time that CGRP partially mediates nitroglycerin effects
n humans through an ALDH-2–dependent mechanism.
he investigators show that acute GTN challenges cause
ystolic blood pressure decreases and increases in heart rate
hat correlate well with increased CGRP levels in plasma. In
ddition, in vitro incubation of cultured peripheral blood
ononuclear cells with GTN increased CGRP mRNA
xpression. The increase in CGRP levels was markedly less
ronounced in cells from individuals with a functional loss
Figure 1 Scheme Depicting the Mechanisms
Underlying the Release of CGRP
When given acutely, nitroglycerin (GTN) is bioactivated by the mitochondrial
aldehyde dehydrogenase (ALDH-2), which acts as a nitrate reductase to convert
the organic nitrate in a dinitrate and NO or a related compound (NOx). This
would in turn activate the soluble guanylyl cyclase (sGC), leading to an
increase in the second messenger cyclic guanosine 3’,5’-monophosphate
(cGMP), activation of the cGMP dependent kinase (cGK-I), and relaxation. NOx
directly and/or indirectly via cGMP is able to cause the release of the calcito-
nin gene-related peptide (CGRP) from sensory nerve fibers, which is also able
to activate sGC, thereby contributing to GTN-induced vasorelaxation. Nitrate
tolerance is associated with an oxidative inhibition of ALDH-2 (by superoxide
O2
.  and/or peroxynitrite ONOO), leading to both a decrease in vascular NOx
bioavailability and CGRP release.f ALDH-2 activity because of a Glu504Lys polymorphism tf the enzyme or in response to its inhibition by chloral
ydrate.
The present studies clearly extend the latest findings
bout GTN metabolism by ALDH-2 (19) and show for the
rst time a contribution of ALDH-2 in the GTN-induced
GRP release in humans. The involvement of the
LDH-2 in GTN-induced effects on hemodynamics such
s blood pressure, heart rate, plasma CGRP level are well
ocumented.
Despite these achievements, several additional issues need
o be addressed in the future. The degree of the contribution
f CGRP to GTN-induced vasodilation remains uncertain.
his issue could be solved by the use of specific CGRP
nhibitors, whenever they will be available for human use.
ther important questions are whether all organic nitrates
in particular mononitrates and dinitrates) and/or other
itrovasodilators, such as sodium nitroprusside, cause vaso-
ilation in humans by increasing CGRP levels, and whether
his effect is mediated by NO or cGMP. It would be also
mportant to study whether a blunting of CGRP release
uring chronic treatment with GTN contributes to the
evelopment of nitrate tolerance.
TN Tolerance and CGRP
nother important issue that needs to be addressed is the
uestion of whether sustained GTN treatment may limit
he potency of GTN to stimulate CGRP release. In 2005,
hen et al. (20) reported that GTN biotransformation and
he activity of the GTN-activating enzyme ALDH-2 were
ecreased in GTN-tolerant vessels, pointing to a crucial role
f ALDH-2 in GTN tolerance.
These observations were extended by our group in an
nimal model of in vivo tolerance (21) and in response to
ong-term clinical GTN application in patients (19) by
howing that reactive oxygen species arising from mito-
hondria inhibited ALDH-2 activity and subsequently
locked the GTN biotransformation process associated with
olerance development. Biochemically, GTN-triggered re-
ctive oxygen species formation caused an oxidation of
ulfhydryl groups at the active site and consequently an
nhibition of the enzyme (Fig. 1). The activity of ALDH-2
an be restored by sulfhydryl-group donors (19,22) and
ntioxidants such as reduced lipoic acid (22). Interestingly,
ecent experimental data indicate that decreased CGRP
elease accounts for in vivo GTN tolerance and that
olerance, as well as CGRP release, can be restored by
reatment with sulfhydryl donors, such as N-acetylcysteine
nd captopril (8). On the other hand, development of in
itro GTN tolerance in rat aortic rings was reported to be
ounteracted by increased CGRP release (23), giving room
or further studies to come.
In conclusion, the findings of Guo et al. (18) further
trengthen the functionally relevant role of ALDH-2 in
TN bioactivation in humans. Their findings also indicatehat the neuropeptide CGRP partially mediates GTN-
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September 9, 2008:961–3 Editorial Commentnduced vasodilation, compatible with the concept that
TN indeed hits the nerve. The mechanistic involvement
f CGRP in GTN-induced vasodilation as well as its
mpact on nitrate tolerance phenomena in humans needs
urther investigation.
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